Selective and Orally Bioavailable c-Met PROTACs for the Treatment of c-Met-Addicted Cancer
Journal of Medicinal Chemistry · 10.10.2024 · 67 (19) · 17053-17069
DOI: 10.1021/acs.jmedchem.3c02417 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 30.09.2024. Verfasst von Shilong Ying und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academ…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Proteolysis, Antineoplastic Agents, Biological Availability. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Health Commission of the People's Republic of China, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
c-Met is an attractive therapeutic target in multiple tumors. Previous studies have discovered some effective proteolysis-targeting chimeras (PROTACs) able to degrade c-Met; however, the structure-activity relationship (SAR), degradation selectivity, and pharmacokinetic profiles of c-Met PROTACs have, to date, remained largely unknown. Herein, through extensive SAR studies on various warheads, linkers, and E3 ligase ligands, a novel potent c-Met PROTAC Met-DD4 was identified. Our results suggested that Met-DD4 could induce robust c-Met degradation with excellent selectivity (DC50 = 6.21 nM), substantially killing the c-Met-addicted cancer cells (IC50 = 4.37 nM). Furthermore, in vivo studies showed that Met-DD4 could achieve excellent oral bioavailability and c-Met degradation, strongly retarding tumor growth with minute organ toxicity. Overall, this study reveals that targeted degradation of c-Met is a promising strategy for the treatment of c-Met-addicted cancers and provides novel lead compounds for the clinical translation of c-Met PROTACs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
- College of Materials Science and Engineering, Zhejiang University of Technology, Hangzhou, Zhejiang 310014, China.
- Insitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei 230601, China.
- Institute of Molecular Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, and College of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
ORCID-Profile: Penghui Zhang, Weihong Tan
Förderung
- National Health Commission of the People's Republic of China
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Zhejiang Leading Innovation and Entrepreneurship Team
Zitieren
APA
Ying, S., Chi, H., Wu, X., Zeng, P., Chen, J., Fu, T., Fu, W., Zhang, P., & Tan, W. (2024). Selective and Orally Bioavailable c-Met PROTACs for the Treatment of c-Met-Addicted Cancer. Journal of Medicinal Chemistry, 67(19), 17053-17069. https://doi.org/10.1021/acs.jmedchem.3c02417
Vancouver
Ying S, Chi H, Wu X, Zeng P, Chen J, Fu T, et al. Selective and Orally Bioavailable c-Met PROTACs for the Treatment of c-Met-Addicted Cancer. Journal of Medicinal Chemistry. 2024;67(19):17053-17069. doi:10.1021/acs.jmedchem.3c02417
BibTeX
@article{Ying2024,
author = {Ying, Shilong and Chi, Hongli and Wu, Xiaoqiu and Zeng, Pingping and Chen, Jinling and Fu, Ting and Fu, Weitao and Zhang, Penghui and Tan, Weihong},
title = {Selective and Orally Bioavailable c-Met PROTACs for the Treatment of c-Met-Addicted Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {19},
pages = {17053--17069},
doi = {10.1021/acs.jmedchem.3c02417}
}
EUVIMED